ABECMA (idecabtagene vicleucel) is a B-cell maturation antigen (BCMA)-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory multiple myeloma after two or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.

This website is best viewed using the horizontal display on your tablet device.

This website is best viewed using the vertical display on your mobile device.

>8x Higher Percentage* of Triple-Class Exposed Patients Achieved ≥CR With ABECMA®1,2

At final analysis, ABECMA provided a statistically significant improvement in ORR vs 5 standard regimens

  • Response data at primary analysis (median follow-up of 15.9 months): ABECMA 71% (n=181) ORR, 60% (n=153) ≥VGPR, 39% (n=98) ≥CR vs standard regimens 42% (n=55) ORR, 15% (n=20) ≥VGPR, 5% (n=7) ≥CR

The KarMMa-3 trial was not powered to evaluate differences in CR rates, therefore such results are not statistically significant and should be interpreted with caution and the significance of such difference is not known.

Data from final PFS analysis. Cutoff date April 28, 2023.

Data from primary PFS analysis.

CI=confidence interval; CR=complete response; mDOR=median duration of response; mPFS=median progression-free survival; ORR=overall response rate; PR=partial response; sCR=stringent complete response; VGPR=very good partial response.

Identify your
ABECMA-eligible patients

Start the ABECMA
process faster
ever—find a certified
treatment center
near you